Loading…
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company conducts wholesale trade in pharmaceutical goods in the free industrial zone.
| Ratio | 2022 | 2023 | 2024 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 42.9% | 30.2% | 43.6% |
| EBITDA Margin | 29.5% | 28.9% | 39.0% |
| EBITDAR | 978 | 1,459 | 1,488 |
| EBITDAR Margin | 29.5% | 29.4% | 39.1% |
| EBIT Margin | 29.5% | 28.7% | 38.8% |
| Net Profit Margin | 34.4% | 27.0% | 40.4% |
| Operating Expense % of Sales | 13.4% | 1.3% | 4.5% |
| Returns | |||
| Return on Assets (ROA) | 67.1% | 45.3% | 49.7% |
| Return on Equity (ROE) | 221.5% | 201.6% | 216.2% |
| ROIC [EBIT / Invested Capital] | 258.5% | 245.3% | 352.7% |
| Leverage & debt balances | |||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 30.3% | 22.5% | 23.0% |
| Net Debt | -136 | -82 | -292 |
| Cash & Equivalents | 136 | 82 | 292 |
| Total Debt | N/A | N/A | N/A |
| Liquidity & working capital | |||
| Current Ratio | 1.44x | 1.29x | 1.29x |
| Quick Ratio | 1.44x | 1.29x | 1.29x |
| Cash Ratio | 0.12x | 0.04x | 0.12x |
| Total Current Assets | 1,700 | 2,958 | 3,082 |
| Total Current Liabilities | 1,184 | 2,293 | 2,383 |
| Inventory | N/A | N/A | N/A |
| Trade Receivables | 448 | 1,439 | 1,572 |
| Trade Payables | 1,184 | 2,293 | 2,383 |
| Net Working Capital | 516 | 665 | 699 |
| Net Working Capital % of Revenue | 15.6% | 13.4% | 18.4% |
| Trade Working Capital | -736 | -854 | -811 |
| Trade Working Capital % of Revenue | -22.2% | -17.2% | -21.3% |
| Change in Trade Working Capital | N/A | -119 | 43 |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A |
| Receivables Turnover | 7.40x | 3.45x | 2.42x |
| Days Sales Outstanding (DSO) | 49.3 | 105.7 | 150.5 |
| Payables Turnover | 1.60x | 1.51x | 0.90x |
| Days Payable Outstanding (DPO) | 228.0 | 241.3 | 404.6 |
| Cash Conversion Cycle | -178.7 days | -135.7 days | -254.0 days |
| Asset Turnover | 1.95x | 1.68x | 1.23x |
| Cash flow & dividends | |||
| Operating Cash Flow | 845 | 1,172 | 1,701 |
| Free Cash Flow (OCF − Capex proxy) | 845 | 1,172 | 1,701 |
| Cash Conversion (OCF / EBITDA) | 86.4% | 81.5% | 114.4% |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →